Royalty Report: Drugs, Viral Infection, Disease – Collection: 275821

Licensor grants an exclusive license, with the right to grant sub licenses, solely under the Licensor Foreign PEG Patents solely to make, use, develop, promote, sell, offer for sale and import PEG-Infergen Products.

INFERGEN (interferon alfacon-1) is a prescription medicine used to treat adults with lasting chronic (lasting a long time) hepatitis C virus (HCV) infection and certain types of liver problems.

Licensor grants an exclusive, even as to Licensor, sublicense, without the right to grant sublicenses, under the Existing License Patents to use, develop, promote, sell, and offer for sale Infergen in the Territory.

Licensor grants an exclusive license, even as to Licensor, under the PEG Patent, to use bulk Infergen to make and have made pegylated Licensed Products.

Licensor grants an exclusive license, even as to Licensor, under PEG Know-How and Patents claiming PEG Know-How, to use bulk Infergen to make and have made pegylated Licensed Products.

For the Trademark and Copyright licenses, Licensor grants an exclusive license, with the right to grant sublicenses, under the entire right, title and interest in and to the Licensor Trademarks, to use and display the Licensor Trademarks in connection with Licensed Products in the Territory.

Licensor grants an exclusive license under Licensors entire right, title and interest in any copyrights in Infergen-specific promotional materials existing on or before the Effective Date, with the right to grant sublicenses, to reproduce, distribute copies of, prepare derivative works of and publicly perform and display such promotional materials in connection with Licensed Products in the Territory.

For the Know-how license, Licensor grants an exclusive license under the Licensor Know-How to use the Licensor Know-How for the sole purposes of using, developing, promoting, selling, offering for sale and importing Licensed Products in the Territory.

The Licensed Product shall mean any product comprising Interferon alfacon-1 or a gene sequence coding therefor, or which delivers Interferon alfacon-1 via gene therapy Licensed Products include but are not limited to Infergen.

PEG Patent shall mean United States Patent Number 5,985,265, United States Application Number 09/408,113 and Canadian Patent Application Number 2,307,142 and any substitution, extension, registration, confirmation, reissue, reexamination, renewal and the like.

PEG-Infergen Product shall mean a pharmaceutical composition containing as its active ingredient a pegylated form of Interferon alfacon-1.

Infergen is indicated for the treatment of hepatitis C

VX-222 is an investigational HCV (Hepatitis C Virus) polymerase inhibitor.  Treatment with VX-222 resulted in mean reductions in plasma HCV RNA of greater than 3 log10.

VX-497, or merimepodib, is a drug for autoimmune diseases.

VX-222 is for the oral Treatment of Hepatitis C.  VX-497, or merimepodib, is an oral treatment for HCV (Hepatitis C Virus) infection.  This agreement Field does not limit the use to HCV, but does limit the use to Anti-infectives and Anti-virals.

With this amendment 5, The parties modify certain provisions of the Agreement relating to the manufacture of Agreement Product, payment of royalties on sales of Agreement Product, and rights under Patent Rights and to use Know-How.  

With this amendment, the grant section is replaced, modifying the exclusivity of the grant, as follows
Licensor grants an exclusive license, exclusive even as to Licensor, under the Licensor Patent Rights, the Existing Know-How and the Licensor Development Know-How, during the term of this Agreement, to make, have made, use, import, export, offer for sale and sell Bulk Concentrate and Agreement Product in the Territory. This license shall include the right to sublicense Licensees Affiliates with respect to making and having made the Bulk Concentrate and Agreement Product, third party vendors with respect to the manufacture of conforming PEG, and its Affiliates or third parties with respect to using importing, exporting, offering for sale and selling Agreement Product.

Licensor grants a non-exclusive license in the Territory under the U-PEG Patent Rights during the term of this Agreement to make, have made, use, import, export, offer for sale and sell pharmaceutical products in which alpha interferon as an active ingredient is coupled with PEG.

Licensor grants a non-exclusive license in the Territory under the Licensed Licensor Patent Rights for all purposes during the term of this Agreement. The license granted includes, without limitation, the right to make, have made, use, import, export, offer for sale and sell pharmaceutical products comprising one or more active ingredients coupled with PEG, and the limited right to grant sublicenses to third party contractors in connection with the discovery, development and commercialization of such products by or on behalf of Licensee or its Affiliates, and/or Licensees, or its Affiliates, third party licensees and/or distributors of such products.

The Agreement Product shall mean any pharmaceutical product in which Agreement Substance as an active ingredient is coupled with PEG.

The patent(s) and products relate to anti-virals.

Intron A belongs to a group of drugs called interferons. This medication works by stopping viruses from dividing and by triggering our immune system to kill invading pathogens or tumors.

Intron A is a prescription medication used to treat chronic hepatitis B, chronic hepatitis C, certain type of genital warts, hairy cell leukemia, malignant melanoma, AIDS-related Kaposi's sarcoma, and follicular lymphoma.